Skip to Main Content

For Kristin Davie, it’s a tempting possibility.

Her 70-year-old mother has late-stage Alzheimer’s, which likely means she would not get a chance to take an experimental drug for the devastating disease being reviewed next month by a regulatory panel. That’s because the clinical trial data for the medicine, called aducanumab, pertains only to patients in the early stages of the disease. But if regulators approve the experimental Biogen (BIIB) therapy next month, Davie might still pursue the drug for her mother.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED